Analysis
Are FDA-approved Ozempic or Zepbound generics available in 2026?
A dated FDA Orange Book check distinguishes approved generics from compounded products, ingredient names and future price announcements.
Claims are checked against the sources cited in this article. Nothing here is individualized medical advice. How we research
On this page
No approved generic semaglutide or tirzepatide products appeared in the FDA Orange Book dataset checked October 9, 2026, whose update date was October 7: all returned ingredient records were new-drug applications, not generic abbreviated applications. Compounded semaglutide and tirzepatide are not FDA-approved generic versions of Ozempic or Zepbound. FDA Orange Book data, FDA compounding explanation.
That is a dated U.S. approval-record finding, not a forecast of when a generic will launch or what it will cost. It is important because online listings often use “generic” to describe an ingredient, an unbranded compounded preparation or simply a cheaper offer. Those descriptions do not establish generic approval.
What the FDA record check found
We checked both active ingredients in FDA’s machine-readable Orange Book dataset and retrieved the complete result sets returned by the service: semaglutide ingredient records and tirzepatide ingredient records. Semaglutide produced 29 product records; tirzepatide produced 48. The response metadata identified October 7, 2026 as the dataset’s last update. This is the Orange Book endpoint, not the separate NDC marketing database or a search-engine count.
| Ingredient searched | Complete returned product records | Application types returned | Generic abbreviated application records |
|---|---|---|---|
| Semaglutide | 29 | N, new-drug applications | 0 |
| Tirzepatide | 48 | N, new-drug applications | 0 |
The FDA field descriptions explain that N identifies an NDA or innovator application and A identifies an ANDA or generic application. The result includes multiple strengths and product forms, not 29 or 48 unrelated medicines. Product-record counts should not be confused with a count of brands, companies or prescribing choices.
FDA’s Orange Book API documentation describes monthly updating and cautions against using the service for medical-care decisions. This check is regulatory reporting with a defined snapshot date. An approval announced after that snapshot would need a separate official record check before updating the conclusion.
“Generic name” is not “approved generic product”
Semaglutide is an ingredient name associated with multiple branded products in the records, including Ozempic, Rybelsus and Wegovy variants. Tirzepatide records include Mounjaro and Zepbound variants. Seeing the ingredient written instead of a brand name does not mean the preparation was approved through the generic application pathway.
A consumer might encounter semaglutide in an article’s ingredient field, a pharmacy description or a seller’s headline. The relevant follow-up is which finished product and approval record that description represents. A shared ingredient name by itself does not identify the same formulation, delivery form, labeling or regulatory category.
Similarly, another brand containing the same ingredient is not automatically an approved generic substitute for the product on a prescription. Ask the pharmacist about the actual prescribed product and any substitution question. This guide reports application status, not clinical interchangeability or instructions to change treatment.
Compounded products have a different regulatory category
FDA’s compounding FAQ explains that compounded finished medicines are not FDA-approved and are not the same regulatory category as approved generics. A licensed pharmacy’s compounded preparation does not acquire generic approval simply because the ingredient name resembles the one in an approved medicine.
The agency also explains that compounding is subject to conditions under federal law. That is separate from the generic approval process. This article does not classify every individual compound as lawful or unlawful; it establishes that calling a compounded product an FDA-approved generic would misidentify its approval status.
Our compounded semaglutide comparison and compounded tirzepatide comparison therefore identify the products as compounded rather than generic Ozempic or generic Zepbound. Their prices describe particular offers and commitments, not evidence of an approved generic launch.
An application-development notice is not an approval
FDA publishes material relevant to future generic development, including Orange Book patent information and certain determinations concerning reference products. Those materials can be useful to applicants without establishing that a new generic product is approved or sold.
For example, an April 30, 2026 FDA notice concerning a discontinued Ozempic presentation determines that it was not withdrawn for safety or effectiveness reasons and discusses the requirements for potential abbreviated applications. That finding is not itself an ANDA approval, a retail launch date or a generic price announcement.
Likewise, a patent-expiration date, a company’s development announcement or a proposed generic application should not be treated as a guarantee of market availability on a particular day. FDA’s generic-drug explanation describes how patents and exclusivities can affect timing. It does not give a universal countdown for these two products.
Lower prices can arrive without a generic launch
Manufacturer self-pay programs, limited introductory offers, insurance decisions and provider-service prices can change independently of generic approval. A headline announcing a lower branded cash price therefore does not demonstrate that a generic exists.
For budgeting, distinguish the exact product price from the care service arranging it. A manufacturer offer may concern a particular strength, quantity and eligibility category; a telehealth membership can be a separate bill. Neither should be labeled a generic price if the supplied medicine is branded or compounded.
Our semaglutide guide and tirzepatide guide link to provider and product information. Use the official offer terms for current cash prices rather than assuming an unverified future generic will be the cheapest available route today.
How to check a seller’s generic claim
Ask for the finished product’s name, manufacturer and FDA application reference. Check it against FDA’s approval resources, not just a search-engine snippet or an ingredient label. If the seller instead identifies a compounded prescription, evaluate it as that category rather than accepting a generic approval claim.
The current answer remains bounded: the October 7 FDA dataset contained no ANDA product records for either ingredient when checked October 9. Keep that date visible, verify any newer official approval separately, and do not mistake cheaper pricing, future development or compounded availability for an approved generic product.